Prescription drug · ANDA
Digoxin NDC 60687-858
Digoxin .125 mg/1 · Tablet · Oral · American Health Packaging
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 60687-858-01 | 60687085801 | 100 BLISTER PACK in 1 CARTON (60687-858-01) / 1 TABLET in 1 BLISTER PACK (60687-858-11)Marketed from Feb 6, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Digoxin
- Generic name (nonproprietary)
- digoxin
- Active ingredients
- Digoxin — .125 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- American Health Packaging
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 215307
- Marketing start
- Listing expires
- Other FDA classes
- Cardiac Glycosides (Chemical structure)
- Identifiers
- Product ID 60687-858_31b908f2-f5f7-176f-e063-6294a90a0bf1SPL ID 31b908f2-f5f7-176f-e063-6294a90a0bf1SPL set ID 5500ee2a-077d-486c-b56d-36e0c5e5c31dRxCUI 197604, 197606UNII 73K4184T59
- Pharmacologic class
- Cardiac Glycoside
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N460687085801followed by a unit qualifier and the quantityPackage 60687-0858-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. (1.1) Increasing myocardial contractility in pediatric patients with heart failure. (1.2) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. (1.3) 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, Digoxin should be used in combination wit…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 215307
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Digoxin | Digoxin .25 mg/1 | TabletOral | American Health Packaging | 60687-869 |
| Digoxin | Digoxin .125 mg/1 | TabletOral | Marlex Pharmaceuticals, Inc. | 10135-747 |
| Digoxin | Digoxin .25 mg/1 | TabletOral | Marlex Pharmaceuticals, Inc. | 10135-748 |
| Digoxin | Digoxin .0625 mg/1 | TabletOral | ANI Pharmaceuticals, Inc. | 70954-200 |
| Digoxin | Digoxin .125 mg/1 | TabletOral | ANI Pharmaceuticals, Inc. | 70954-201 |
| Digoxin | Digoxin .25 mg/1 | TabletOral | ANI Pharmaceuticals, Inc. | 70954-202 |
| Digoxin | Digoxin .125 mg/1 | TabletOral | Northwind Health Company, LLC | 51655-403 |